BR112022022081A2 - Composição farmacêutica inalável, método para tratar uma infecção viral pulmonar, pó seco inalável, composição farmacêutica, sistema de inalação para o uso no tratamento ou profilaxia de uma infecção viral pulmonar - Google Patents
Composição farmacêutica inalável, método para tratar uma infecção viral pulmonar, pó seco inalável, composição farmacêutica, sistema de inalação para o uso no tratamento ou profilaxia de uma infecção viral pulmonarInfo
- Publication number
- BR112022022081A2 BR112022022081A2 BR112022022081A BR112022022081A BR112022022081A2 BR 112022022081 A2 BR112022022081 A2 BR 112022022081A2 BR 112022022081 A BR112022022081 A BR 112022022081A BR 112022022081 A BR112022022081 A BR 112022022081A BR 112022022081 A2 BR112022022081 A2 BR 112022022081A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- pharmaceutical composition
- viral infection
- inhalable
- pulmonary viral
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title abstract 5
- 238000011282 treatment Methods 0.000 title abstract 5
- 230000009385 viral infection Effects 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 230000002685 pulmonary effect Effects 0.000 title abstract 4
- 238000011321 prophylaxis Methods 0.000 title abstract 3
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 abstract 1
- 229960004287 clofazimine Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063018677P | 2020-05-01 | 2020-05-01 | |
| PCT/US2021/030155 WO2021222740A1 (en) | 2020-05-01 | 2021-04-30 | Clofazimine composition and method for the treatment or prophylaxis of viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022022081A2 true BR112022022081A2 (pt) | 2022-12-13 |
Family
ID=78332269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022022081A BR112022022081A2 (pt) | 2020-05-01 | 2021-04-30 | Composição farmacêutica inalável, método para tratar uma infecção viral pulmonar, pó seco inalável, composição farmacêutica, sistema de inalação para o uso no tratamento ou profilaxia de uma infecção viral pulmonar |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230248722A1 (enExample) |
| EP (1) | EP4142691A4 (enExample) |
| JP (1) | JP2023524064A (enExample) |
| KR (1) | KR20230005937A (enExample) |
| CN (1) | CN115666510A (enExample) |
| AU (1) | AU2021263580A1 (enExample) |
| BR (1) | BR112022022081A2 (enExample) |
| CA (1) | CA3177438A1 (enExample) |
| WO (1) | WO2021222740A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240390366A1 (en) * | 2021-11-30 | 2024-11-28 | Mannkind Corporation | Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers |
| WO2025091042A1 (en) * | 2023-10-27 | 2025-05-01 | Mannkind Corporation | Methods for treating non-tuberculous mycobacterial infection |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071127B2 (en) * | 2006-10-24 | 2011-12-06 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| ES2929343T3 (es) | 2008-06-13 | 2022-11-28 | Mannkind Corp | Inhalador de polvo seco accionado por aspiración para la administración de fármacos |
| EP2496253B1 (en) * | 2009-11-02 | 2019-01-09 | MannKind Corporation | Apparatus and method for cryogranulating a pharmaceutical composition |
| AU2014228415B2 (en) * | 2013-03-15 | 2018-08-09 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
| CA2943049A1 (en) * | 2014-04-08 | 2015-10-15 | Aradigm Corporation | Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria |
| CA2965258C (en) * | 2014-10-24 | 2023-09-19 | Redhill Biopharma Ltd. | Therapy for inhibition of single-stranded rna virus replication |
| US20160220710A1 (en) * | 2015-01-30 | 2016-08-04 | The Regents Of The University Of Michigan | Compositions and methods for delivering pharmaceutical agents |
| CN108853106B (zh) * | 2017-05-09 | 2021-02-02 | 中国食品药品检定研究院 | 亚胺吩嗪类化合物作为狂犬病病毒抑制剂的用途 |
| US20200297626A1 (en) * | 2017-10-02 | 2020-09-24 | Board Of Regents, The University Of Texas System | Inhalable composition of clofazimine and methods of use thereof |
| WO2019110099A1 (en) * | 2017-12-06 | 2019-06-13 | Qrumpharma Inc. | Inhalable clofazimine formulation |
| KR102834026B1 (ko) * | 2018-08-23 | 2025-07-14 | 맨카인드 코포레이션 | 클로파지민의 조성물, 이들을 포함하는 조합물, 이들의 제조 방법, 이들을 포함하는 용도 및 방법 |
-
2021
- 2021-04-30 CA CA3177438A patent/CA3177438A1/en active Pending
- 2021-04-30 BR BR112022022081A patent/BR112022022081A2/pt unknown
- 2021-04-30 JP JP2022566323A patent/JP2023524064A/ja active Pending
- 2021-04-30 KR KR1020227041996A patent/KR20230005937A/ko active Pending
- 2021-04-30 US US17/996,706 patent/US20230248722A1/en active Pending
- 2021-04-30 AU AU2021263580A patent/AU2021263580A1/en active Pending
- 2021-04-30 CN CN202180031573.9A patent/CN115666510A/zh active Pending
- 2021-04-30 WO PCT/US2021/030155 patent/WO2021222740A1/en not_active Ceased
- 2021-04-30 EP EP21796019.4A patent/EP4142691A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023524064A (ja) | 2023-06-08 |
| EP4142691A4 (en) | 2024-05-15 |
| US20230248722A1 (en) | 2023-08-10 |
| AU2021263580A1 (en) | 2022-11-24 |
| EP4142691A1 (en) | 2023-03-08 |
| CN115666510A (zh) | 2023-01-31 |
| CA3177438A1 (en) | 2021-11-04 |
| KR20230005937A (ko) | 2023-01-10 |
| WO2021222740A1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017010551A2 (pt) | composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento. | |
| BR112016022598A8 (pt) | composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso | |
| BR112016026699A8 (pt) | uso de amicacina ou de um sal farmaceuticamente aceitável desta | |
| CO2022014073A2 (es) | Compuestos antivirales y métodos para la administración de los mismos | |
| Alkotaji | Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2 | |
| BR112021021637A2 (pt) | Vacina de subunidade para tratamento ou prevenção de uma infecção do trato respiratório | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BR112015025766A2 (pt) | derivado de nucleosídeo altamente ativo para o tratamento de hcv | |
| BR112017020039A2 (pt) | composição farmacêutica, kit, método, processo para preparar uma composição e solução farmacêutica | |
| BR112014029735A2 (pt) | forma de dosagem e formulação de abediterol | |
| BR112022019519A2 (pt) | Tratamento | |
| JP2014028839A5 (enExample) | ||
| BR112018068075A2 (pt) | inibidores de fosfatidilinositol 3-quinase gama | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| BR112022022081A2 (pt) | Composição farmacêutica inalável, método para tratar uma infecção viral pulmonar, pó seco inalável, composição farmacêutica, sistema de inalação para o uso no tratamento ou profilaxia de uma infecção viral pulmonar | |
| NO20063047L (no) | Vandige ciclesonidsuspensjoner for forstoving | |
| ES2570401T3 (es) | Métodos de tratamiento usando dosis únicas de oritavancina | |
| WO2020037095A1 (en) | Egcg-palmitate compositions and methods of use thereof | |
| BR112021018815A2 (pt) | Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário | |
| BR112018072177A2 (pt) | composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta | |
| MX2020010977A (es) | Procedimientos de tratamiento de infecciones fúngicas. | |
| WO2016137806A3 (en) | Doses and methods of administering telavancin | |
| EP4190333A1 (en) | Azelastine as antiviral treatment | |
| BR112023003987A2 (pt) | Composição farmacêutica compreendendo hidroxicloroquina e seus usos | |
| BR112013020632A8 (pt) | Composição farmacêutica para a administração tópica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |